SUMITOMO CHEMICAL (4005) FY2027 Q1 Earnings Report

Quick View

Executive Summary

For Q1 of the fiscal year ending March 2027, Sumitomo Chemical reported higher revenue and higher earnings, with Operating Income and Net Income recovering substantially on improved market conditions for materials and a return to profitability in equity-method investment gains and losses. Revenue was ¥578.20B (¥526.14B in the same period of the previous year, +9.9%), Operating Income was ¥61.04B (¥25.45B, +139.8%), Profit Before Tax was ¥60.31B (¥5.82B, +936.8%), and Net Income was ¥51.35B (¥3.87B, +1225.8%). Profit for the quarter attributable to owners of the parent was ¥40.78B, representing a return to profitability from a loss of ¥4.52B in the same period of the previous year. The primary drivers of earnings growth were the turnaround in Core Operating Income for Essential & Green Materials and improvement in equity-method investment gains and losses.

Factors Affecting Performance

【Revenue】Revenue was ¥578.20B, representing a +9.9% year-on-year increase. By segment, Sumitomo Pharma grew +20.2%, Advanced Medical Solutions grew +15.0%, and Agro & Life Solutions grew +12.5%, while Essential & Green Materials posted relatively low growth of +2.9%. All segments reported higher revenue, indicating firm demand across the overall business portfolio.

【Profit and Loss】Operating Income was ¥61.04B (+139.8%), and the Operating Margin improved to 10.6% from 4.8% in the same period of the previous year, an improvement of 572bp. The gross margin improved to 33.6% from 31.1%, while operating leverage was achieved as the +9.9% increase in revenue exceeded the +8.9% increase in SG&A expenses. The primary contributor to earnings growth was the turnaround in Core Operating Income for Essential & Green Materials, from a loss of ¥5.46B in the same period of the previous year to profit of ¥27.22B. Equity-method investment gains and losses also turned from a loss of ¥9.83B to a gain of ¥12.22B, supporting Operating Income. In contrast, ICT & Mobility Solutions reported a -29.0% YoY decline in profit despite higher revenue, while Sumitomo Pharma also reported a -10.3% YoY decline in profit despite higher revenue, highlighting divergent performance by business. Financial income of ¥12.55B and financial expenses of ¥13.28B almost offset each other, resulting in Profit Before Tax of ¥60.31B, close to Operating Income. Revenue and earnings both increased.

Segment Analysis

Essential & Green Materials was the largest driver of company-wide earnings growth, reporting revenue of ¥170.19B (+2.9%) and Operating Income of ¥27.22B (+598.3%, 16.0% margin). Agro & Life Solutions improved significantly, with revenue of ¥108.99B (+12.5%) and Operating Income of ¥9.63B (+334.0%, 8.8% margin). Sumitomo Pharma reported higher revenue of ¥129.00B (+20.2%) but lower Operating Income of ¥18.85B (-10.3%). ICT & Mobility Solutions likewise reported higher revenue of ¥148.57B (+8.1%) but lower Operating Income of ¥13.03B (-29.0%). Advanced Medical Solutions increased revenue to ¥10.45B (+15.0%), but its operating loss widened to ¥1.94B (loss of ¥0.92B in the previous year). Company-wide earnings growth depended on the improvement of the two materials-related segments, while profitability pressure continued in the pharmaceutical- and ICT-related businesses.

Key Financial Metrics

【Profitability】Operating Margin improved substantially to 10.6% from 4.8%, while Net Profit Margin improved to 8.9% from 0.7%. The gross margin also increased to 33.6% from 31.1%. Annualized ROE was 14.5%, confirming a recovery in returns on shareholders’ equity, including the contribution from financial leverage.【Cash Flow Quality】Operating Cash Flow (OCF) was limited to ¥4.96B, and the OCF/Net Income ratio relative to profit attributable to owners of the parent was approximately 0.12x, a low level, indicating that cash conversion is lagging the recovery in accounting earnings. Inventories increased to ¥643.62B (+¥48.15B versus the beginning of the period), while trade receivables increased to ¥644.53B (+¥35.86B versus the beginning of the period). Improvement in inventory and receivables turnover will therefore be an area to monitor.【Investment Efficiency】Equity-method investment income was ¥12.22B, accounting for approximately 20% of Operating Income and making a significant contribution to earnings improvement.【Financial Soundness】The Equity Ratio improved slightly to 30.5% from 29.6%. Current assets were ¥1,659.06B and current liabilities were ¥1,103.84B, resulting in a current ratio of approximately 150% and confirming adequate short-term liquidity. However, short-term interest-bearing debt increased to ¥288.55B (+¥47.13B versus the beginning of the period).

Cash Flow Analysis

Operating Cash Flow was ¥4.96B, a substantial -79.3% year-on-year decline, resulting in a significant divergence from Profit Before Tax of ¥60.31B. This divergence was primarily attributable to an increase of ¥62.59B in inventories and an outflow of ¥117.01B in other working capital, partially offset by a ¥92.55B increase in operating liabilities. Investing Cash Flow was -¥49.23B, mainly due to the acquisition of property, plant and equipment of ¥35.91B and an increase of ¥12.31B in time deposits. Free Cash Flow was -¥44.27B, indicating that during the quarter, operating activities alone did not support investment and dividends. Financing Cash Flow was an inflow of ¥55.57B, with capital contributions from non-controlling interests of ¥96.88B covering funding requirements for investment and working capital. As a result, cash and cash equivalents increased from ¥20.86B at the beginning of the period to ¥22.32B, although the increase was dependent on financing.

Earnings Quality

The recovery in earnings during the quarter was generally attributable to improvement in recurring business profitability, excluding ¥1.07B in business-structure improvement expenses, and temporary factors were limited. Operating Income included other operating income of ¥3.55B and other operating expenses of ¥3.37B; their net contribution was small at ¥0.18B. The main drivers of earnings improvement were improved profitability in core businesses and the turnaround in equity-method investment gains and losses. Financial income of ¥12.55B and financial expenses of ¥13.28B were broadly balanced, and financial items did not materially distort earnings. However, the fact that OCF did not keep pace with the increase in Net Income, with the OCF/profit attributable to owners of the parent ratio remaining at approximately 0.12x, warrants attention from an accruals perspective. Earnings growth accompanied by increases in inventories and trade receivables remains weakly supported by cash flow. Comprehensive income was ¥91.65B (¥78.94B attributable to owners of the parent), exceeding Net Income of ¥51.35B, with foreign-exchange-related other comprehensive income, including foreign currency translation adjustments of ¥13.21B, providing an additional contribution.

Earnings Forecast and Guidance

The full-year company forecast is Revenue of ¥2,360.0B, Operating Income of ¥177.00B (+16.6% year-on-year), EPS of ¥42.40, and dividends of ¥16.00 per share. Progress against the full-year forecast in Q1 was approximately 24.5% for Revenue and approximately 34.5% for Operating Income, with Operating Income exceeding the standard quarterly progress rate of 25%. Profit attributable to owners of the parent was ¥40.78B in Q1, representing approximately 58.3% of the full-year forecast of ¥70.00B and substantially ahead of schedule. Neither the earnings forecast nor the dividend forecast had been revised as of the end of the quarter.

Shareholder Returns

The full-year dividend forecast is ¥16.00 per share, an increase from the previous-year dividend of ¥6.00 (based on the actual dividend for the same period of the previous year). Dividend payments during Q1 were ¥12.39B, representing approximately 30.4% of profit attributable to owners of the parent of ¥40.78B for the quarter. Based on the full-year forecast, the Payout Ratio is estimated at approximately 37.7%, calculated using total dividends of approximately ¥26.42B, based on the average number of shares outstanding during the period of 1.651B shares × ¥16.00, against the full-year forecast of ¥70.00B in profit attributable to owners of the parent. Share repurchases were virtually nonexistent (-¥0.00B), indicating a shareholder-return policy focused solely on dividends.

Risk Factors

1. Delay in cash conversion: Operating Cash Flow was limited to ¥4.96B, and the OCF/Net Income ratio relative to profit attributable to owners of the parent of ¥40.78B was approximately 0.12x, a low level. The main factors were the ¥62.59B increase in inventories and the outflow in other working capital, resulting in Free Cash Flow of -¥44.27B. Whether earnings improvement will translate into cash generation will be a key point of future monitoring.

2. Variation in segment profitability: ICT & Mobility Solutions (profit YoY -29.0%) and Sumitomo Pharma (profit YoY -10.3%) reported lower earnings despite higher revenue. Company-wide earnings growth depends on improvement in Essential & Green Materials and Agro & Life Solutions, and any reversal in these trends could affect achievement of the full-year Operating Income target of ¥177.00B.

3. Working capital and inventory levels: Inventories were ¥643.62B and trade receivables were ¥644.53B, both increasing from the beginning of the period. Given the business mix, which includes chemical and pharmaceutical operations, the potential impact of fluctuations in raw material and fuel prices and product demand on inventory valuation and capital efficiency should be monitored.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Both profitability metrics exceed the industry median, placing the company at a relatively high level within the manufacturing industry.

Growth and Capital Efficiency

The revenue growth rate also exceeds the industry median, placing the company in the upper-tier group.

※Source: Compiled by the Company

Key Points in the Earnings Results

1. The Operating Margin improved by 572bp to 10.6% from 4.8% in the previous year. A distinguishing feature is that earnings growth was led by the turnaround in Essential & Green Materials and the return to profitability in equity-method investment gains and losses.

2. Q1 progress against the full-year plan was 34.5% for Operating Income and 58.3% for profit attributable to owners of the parent, both ahead of schedule. However, this represents a recovery in accounting earnings and has not been accompanied by a recovery in OCF. The divergence between profit and cash flow will be a key point of future observation.

3. ICT & Mobility Solutions and Sumitomo Pharma reported higher revenue but lower earnings, resulting in an earnings-growth structure dependent on improvement in the materials-related segments. This is an important consideration when assessing the quality of full-year earnings.

Theoretical Share Price (Reference Value)

Sensitivity: ¥608–¥643 for ±1% in the cost of equity, and ¥624–¥626 for ω±0.1.

Notes:

• Because progress in Net Income against the full-year forecast (58%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies running ahead of forecast progress tend to exceed their forecasts. The adjustment may be excessive for businesses with strong seasonality).
• Net Income is substantially compressed relative to Operating Income due to tax expenses, acquisition-related expenses, and non-controlling interests (Net Income ÷ Operating Income 40%). This value reflects that compression at face value; if the factors are temporary, underlying earnings power may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value Per Share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---